References
- Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109: 31–39
- Olsen E A, Kim Y H, Kuzel T M, Pacheco T R, Foss F M, Parker S, et al. A Phase IIb Multicenter Trial of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Persistent, Progressive or Treatment Refractory Cutaneous T-cell Lymphoma. J Clin Oncol 2007; 25: 3109–3115
- Mitsiades C S, Mitsiades N S, McMullan C J, Poulaki V, Shringarpure R, Hideshima T, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 2004; 101: 540–545
- Mitsiades N, Mitsiades C S, Richardson P G, McMullan C, Poulaki V, Fanourakis G, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003; 101: 4055–4062
- Fandy T E, Shankar S, Ross D D, Sausville E, Srivastava R K. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 2005; 7: 646–657
- Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–1123
- Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda W G, et al. Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008; 111: 1060–1066
- Kelly W K, O'Connor O A, Krug L M, Chiao J H, Heaney M, Curley T, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23: 3923–3931
- Rubin E H, Agrawal N G, Friedman E J, Scott P, Mazina K E, Sun L, et al. A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin Cancer Res 2006; 12: 7039–7045
- Richardson P G, Sonneveld P, Schuster M W, Irwin D, Stadtmauer E A, Facon T, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol 2007; 137: 429–435
- Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson P G, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165–172
- Richardson P G, Sonneveld P, Schuster M W, Irwin D, Stadtmauer E A, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498
- Ghobrial I M, Leleu X, Hatjiharissi E, Hideshima T, Mitsiades C, Schlossman R, et al. Emerging drugs in multiple myeloma. Expert Opin Emerg Drugs 2007; 12: 155–163
- Hideshima T, Anderson K C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002; 2: 927–937
- Nawrocki S T, Carew J S, Pino M S, Highshaw R A, Andtbacka R H, Dunner K, et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006; 66: 3773–3781
- Pei X Y, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004; 10: 3839–3852